RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
AC Immune poleaxed on Alzheimer’s study failShares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a Share XAC Immune poleaxed on Alzheimer’s study failhttps://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Roche hops on Bicycle’s drug discovery platform for cancerRoche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics – Share XRoche hops on Bicycle’s drug discovery platform for cancerhttps://pharmaphorum.com/news/roche-hops-on-bicycles-drug-discovery-platform-for-cancer/
The promise and pitfalls of molecular testing in oncologyGreat strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain Share XThe promise and pitfalls of molecular testing in oncologyhttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/research-partnership-molecular-testing-cancer/
Genentech extends small-molecule R&D with three platform dealsRoche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its Share XGenentech extends small-molecule R&D with three platform dealshttps://pharmaphorum.com/news/genentech-extends-small-molecule-rd-with-three-platform-deals/
Roche and AbbVie’s Venclexta approved in CLLRoche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for Share XRoche and AbbVie’s Venclexta approved in CLLhttps://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/
Genentech brings back Alexander Hardy to take CEO positionRoche has filled the open CEO position at Genentech with Alexander Hardy, a veteran of the subsidiary. The Share XGenentech brings back Alexander Hardy to take CEO positionhttps://pharmaphorum.com/news/genentech-brings-back-alexander-hardy-ceo-position/
Affimed and Roche ink $5bn plus cancer immunotherapy dealDeal is based on natural killer cell therapeutics Share XAffimed and Roche ink $5bn plus cancer immunotherapy dealhttps://pharmaphorum.com/news/affimed-and-roche-ink-5bn-plus-cancer-immunotherapy-deal/